D&MD s Model Organisms in Drug Discovery and Development: An Industry Analysis maps the market opportunity and trends apparent in the model organisms space as they relate to drug discovery and development.
The Report provides comparisons of the various model organisms being deployed currently by the pharmaceutical and biotechnology companies. It also presents the value proposition presented by each of the model systems to the drug discovery and development marketplace. Key company profiles are included to illustrate the scope of offering of the various players, technology platforms utilized, and business model deployed, in the model organisms space
TABLE OF CONTENTS
Chapter 1: Executive Summary
- Scope of this Report
- Summary of Findings in this Report
- Market Segmentation of the Model Organisms Space: Why Model Organisms and Where Do They Fit in Drug Discovery and Development?
- Model Organisms and the Various Disease Areas Where they are Currently Being Deployed
- Overview of the Competitive Landscape
- Opportunities in the Model Organisms Space and Direction of the Field
Chapter 2: Current and Emerging Model Organisms in Drug
- Discovery and Development
- Scope of this Chapter
- Introduction
- The Various Model Organisms Deployed in Drug Discovery and Development
- Caenorhabditis elegans (C. elegans)
- Zebra.sh (Danio rerio)
- Diseases where Zebra.sh have had Impact as a Model System
- Cancer Biology and Apoptosis
- The Mouse (Mus musculus or Mus spretus)
- The Rat
- The Fruit Fly (Drosophila melanogaster)
- Summary
- Comparisons Across the Model Organisms Landscape: Current and Emerging Model Organisms
- Relevant Scienti.c Literature References in the Model Organisms Space Cited in this Chapter
Chapter 3: Market Opportunity in the Model Organisms Space
- Scope of this Chapter
- Proprietary End-user Survey Administered by D&MD
- Quantitative Market Parameters
- Qualitative Factors Affecting the Model Organisms Marketplace
- What technology and market trends in the model organisms space
- Drug discovery and development segments in which animal models are
- being deployed and are they growing or declining:
- Key technologies used in conjunction with animal models
- Novel and emerging animal models for pharmaceutical R&D:
- Unmet needs in the pharmaceutical R&D space:
- Current Technology and Market Trends in Model Organisms for Drug Discovery and
- Development
- Intellectual Property (Patent) Volume and Trends in the Model Organisms Space
- Quantitative Market Modeling of the Model Organisms Space
- Strategic Analysis and Trends in the Model Organisms Space
Chapter 4: Deploying Model Organisms in Drug Discovery and Development Presentation
Chapter 5: Company Pro.les
- AVEO Pharmaceuticals, Inc.
- BioMarker Pharmaceuticals, Inc.
- Cambria Biosciences
- Chronogen
- Danio Labs
- Devgen
- Discovery Genomics
- Exelixis
- ARTEMIS Pharmaceuticals GmbH
- Ingenium Pharmaceuticals AG
- Lexicon Genetics Inc.
- Phenomix
- Phylonix Pharmaceuticals, Inc.
- Union Biometrica
- Xenogen
- Zygogen, LLC
TABLE OF EXHIBITS
- Exhibit 1.1 Business Models in the Model Organisms Space
- Exhibit 1.2 Various Model Organisms and the Disease Areas Where They Are Deployed Currently
- Exhibit 1.3 Summary of the Competitive Landscape in the Model Organisms Space
- Exhibit 2.1 Advantages of the Zebra.sh over the Mouse as a Model System to Study Human Diseases
- Exhibit 2.2 Comparative Analysis of the Model Organisms Space (Features and Bene.ts)
- Exhibit 3.1 Key Challenges in the Deployment of Model Organisms in Drug Discovery
- Exhibit 3.2 The Top Drivers in the Model Organisms Marketplace
- Exhibit 3.3 Total Screening in the Pharmaceutical Industry Performed Using Animal Models
- Exhibit 3.4 Expectation of Growth/Decline in Cost Per Data Point Allocated to Model Organisms
- Exhibit 3.5 The Market Landscape and its Expected Evolution in the Model Organisms Space
- Exhibit 3.6 Model Organisms Patents Distributed by Year of Filing
- Exhibit 3.7 Assignees of Model Organism Patents
- Exhibit 3.8 Model Organism Patents Grouped by Assignee Country
- Exhibit 3.9 Business Model of Companies in the Model Organisms Space
- Exhibit 3.10 Adoption Curve: Model Organisms Marketplace with Time
- Exhibit 3.11 No Clear Winner Yet in the Model Organisms Space: Market Opportunity Exists for New Entrants
